{
    "nct_id": "NCT03100045",
    "official_title": "A Phase I Study of Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)",
    "inclusion_criteria": "* Age ≥ 18 years\n* Biopsy-confirmed high-grade anal dysplasia (AIN 2, AIN 3, HSIL) by high resolution anoscopy (HRA)\n* Female of childbearing potential: negative urine pregnancy test\n* Able to provide informed consent\n* Patients who have the ability to collaborate with planned follow-up (transportation, compliance history, etc.).\n* Weight ≥50 kg.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* Diagnosis of low-grade anal dysplasia (AIN 1, LSIL) by high resolution anoscopy\n* Known anal, vulvar, cervical, or penile cancer\n* CD4 count < 200 at the time of consideration for entry into this study\n* Unable to provide informed consent\n* Currently receiving systemic chemotherapy or radiation therapy for another cancer.\n* Patients who are on medical treatment with systemic immunosuppressants or steroids (e.g., active autoimmune disease)\n* Extensive anal condyloma precludes the ability for the clinician to visualize HSIL during HRA",
    "miscellaneous_criteria": ""
}